DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2019 của Mersana Therapeutics

Mersana is rewriting the rules for immunoconjugate therapies by leveraging their Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. Their Fleximer platform allows them to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug’s chances of effectively attacking a particular cancer. They engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because they can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana’s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

TÊN CÔNG TY / COMPANY
Mersana Therapeutics

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
MRSN

KỲ BÁO CÁO
2019

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare